March 26 (Reuters) - Viking Therapeutics said on Tuesday its experimental tablet helped reduce weight in patients in an early-stage trial and was shown to be safe and effective in the study.
The company said it plans to initiate a phase 2 trial later this year, based on the early-stage data. (Reporting by Manas Mishra in Bengaluru; Editing by Shounak Dasgupta)
These stocks have tremendous potential, and it doesn't depend on the growth prospects for artificial intelligence.
The FDA approved Pfizer's hemophilia gene therapy on Friday. But Pfizer stock only inched ahead on the approval early Friday.
Kraft Heinz CEO Carlos Abrams-Rivera eats just two meals a day, between 11 a.m. and 7 p.m., as part of his intermittent-fasting routine.
Eli Lilly may be on the verge of another breakthrough, thanks to its hit GLP-1 medications.
ResMed stock jumped Friday after crushing sales estimates and wiping out worries that weight-loss drugs would squeeze sleep apnea device sales.
Friday, the FDA approved Pfizer Inc’s (NYSE:PFE) Beqvez (fidanacogene elaparvovec-dzkt) for moderate to severe hemophilia B in adult patients who currently use factor IX (FIX) prophylaxis therapy or have current or historical life-threatening hemorrhage, or have repeated, serious spontaneous bleeding episodes, and do not have neutralizing antibodies to adeno-associated virus serotype Rh74var capsid. Beqvez is a one-time treatment designed to enable hemophilia B patients to produce FIX themselves
Making work pay in Knowsley has always been an uphill battle.
With the US obesity rate hovering at around 40%, tens of millions of Americans could take GLP-1 drugs over the next few years.
Nancy Pelosi's husband Paul Pelosi uses an investing strategy that lowers upfront costs.
One of the world's most successful hedge fund managers has one of the most concentrated portfolio's in the business.